B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

17.44 +0.08 (+0.46%)
Streaming Delayed Price Updated: 2:03 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Should you consider ADMA BIOLOGICS INC (NASDAQ:ADMA) for growth investing? ↗
A fundamental analysis of (NASDAQ:ADMA): Exploring growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA). 
Via Chartmill
News headline image
Would Mark Minervini consider ADMA BIOLOGICS INC (NASDAQ:ADMA) a top stock pick? ↗
A fundamental and technical analysis of (NASDAQ:ADMA): Exploring ADMA BIOLOGICS INC (NASDAQ:ADMA)'s high growth characteristics. 
Via Chartmill
News headline image
ADMA Biologics Inc (NASDAQ:ADMA): A Strong Minervini Trend Template Candidate ↗
ADMA Biologics Inc (NASDAQ:ADMA): A Strong Minervini Trend Template Candidate 
Via Chartmill
News headline image
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
What's Driving the Market Sentiment Around ADMA Biologics? ↗
 
Via Benzinga
News headline image
Peering Into ADMA Biologics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
What's Going On With ADMA Stock Monday? ↗
ADM shares are trading higher Monday after the company announced the FDA's approval of its yield enhancement process. 
Via Benzinga
News headline image
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
News headline image
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval ↗
The company says a new process will improve its output by 20%, benefitting revenue and earnings later this year. 
Via Investor's Business Daily
News headline image
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock. ↗
A fundamental and technical analysis of (NASDAQ:ADMA): Is ADMA BIOLOGICS INC (NASDAQ:ADMA) suited for high growth investing? 
Via Chartmill
News headline image
Investors seeking growth at a reasonable cost should explore ADMA BIOLOGICS INC (NASDAQ:ADMA). ↗
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
ADMA Biologics Statement on Tariffs
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
What's Driving the Market Sentiment Around ADMA Biologics? ↗
 
Via Benzinga
News headline image
ADMA BIOLOGICS INC (NASDAQ:ADMA) is showing good growth, while it is not too expensive. ↗
NASDAQ:ADMA is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
News headline image
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook ↗
CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024. 
Via Stocktwits
News headline image
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 3, 2025 ↗
 
Via Benzinga
News headline image
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week ↗
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter. 
Via Stocktwits
News headline image
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
News headline image
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025. 
Via MarketBeat
Topics ETFs Economy
News headline image
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 ↗
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86. 
Via Investor's Business Daily
News headline image
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
SpringWorks Therapeutics Stock Gets A RS Rating Lift ↗
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76. 
Via Investor's Business Daily
News headline image
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
From ADMA Biologics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.